InflaRx N.V. (NASDAQ:IFRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of InflaRx N.V. (NASDAQ:IFRX) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $7.4286.

Several research firms have commented on IFRX. Weiss Ratings reissued a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th. Cantor Fitzgerald upped their target price on InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Zacks Research downgraded InflaRx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 25th. Finally, Needham & Company LLC initiated coverage on InflaRx in a report on Monday. They set a “buy” rating and a $8.00 price target on the stock.

Hedge Funds Weigh In On InflaRx

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC purchased a new stake in InflaRx during the second quarter worth about $25,000. AXQ Capital LP bought a new position in shares of InflaRx during the 2nd quarter valued at approximately $41,000. ADAR1 Capital Management LLC purchased a new stake in shares of InflaRx during the 1st quarter worth approximately $142,000. DCF Advisers LLC bought a new stake in shares of InflaRx in the 4th quarter worth approximately $160,000. Finally, T3 Companies LLC purchased a new position in InflaRx in the fourth quarter valued at approximately $294,000. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Price Performance

IFRX opened at $2.06 on Friday. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95. The company has a market capitalization of $303.58 million, a price-to-earnings ratio of -3.55 and a beta of 2.52. The firm’s fifty day moving average price is $2.00 and its two-hundred day moving average price is $1.78.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04). As a group, equities analysts anticipate that InflaRx will post -0.31 EPS for the current year.

About InflaRx

InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company’s research centers on the complement system, an important part of the immune response, with particular emphasis on blocking the activity of complement component C5a, which can contribute to excessive inflammation and tissue damage.

InflaRx’s lead product candidate is vilobelimab, a monoclonal antibody designed to selectively inhibit C5a while preserving other aspects of the complement system.